R&D Tax Incentive Review November 2016 (V1)

A recent review of the current R&D Tax Incentive has recommended a maximum cash rebate of $2M of companies with a turnover of less than $20M. AusBiotech would like to gather some qualitative data to assist us in representing the views of the sector.

This survey is aimed at SMEs eligible for the refundable component of the R&D Tax Incentive. Please indicate how this proposed change will impact your company in the nine questions below. If you have any additional documentation to demonstrate how the proposed cap on the R&D Tax Incentive will impact your company, please send to Lorraine Chiroiu, Deputy Chief Executive Officer, AusBiotech, at lchiroiu@ausbiotech.org.

Question Title

* 1. Details (optional)

Name

Company

Address 1

City/town

State/province

ZIP/postal code

Email address

Question Title

* 2. Will a $2M cap reduce your company’s ability to employ new staff or maintain the current level of employment? If so, estimate the extent to which staff numbers or plans to employ will be reduced.

Year 1

Year 2

Question Title

* 3. Will the proposed changes impact the time your company needs to meet your next value inflection milestone? (i.e. first-in-man studies, time to market). If so, estimate the delay and/or provide an example of a milestone that will be impacted.

Question Title

* 4. Will proposed changes delay your company’s revenue from export? If so, estimate the time delay your company may experience for manufacturing and/or exporting.

Question Title

* 5. Will the proposed changes reduce your company’s ability to absorb interns or STEM graduates?

Question Title

* 6. How many private dollars are raised for every public dollar received via the R&D tax rebate?

Question Title

* 7. Does the incentive make it easier for your company to attract foreign or domestic direct investment? Please provide an example.

Question Title

* 8. If there is no impact on capital availability, will the price be materially higher?

Yes

R&D Tax Incentive Review November 2016 (V1)

Question Title

* 1. Details (optional)

Question Title

* 2. Will a $2M cap reduce your company’s ability to employ new staff or maintain the current level of employment? If so, estimate the extent to which staff numbers or plans to employ will be reduced.

Question Title

* 3. Will the proposed changes impact the time your company needs to meet your next value inflection milestone? (i.e. first-in-man studies, time to market). If so, estimate the delay and/or provide an example of a milestone that will be impacted.

Question Title

* 4. Will proposed changes delay your company’s revenue from export? If so, estimate the time delay your company may experience for manufacturing and/or exporting.

Question Title

* 5. Will the proposed changes reduce your company’s ability to absorb interns or STEM graduates?

Question Title

* 6. How many private dollars are raised for every public dollar received via the R&D tax rebate?

Question Title

* 7. Does the incentive make it easier for your company to attract foreign or domestic direct investment? Please provide an example.

Question Title

* 8. If there is no impact on capital availability, will the price be materially higher?

Question Title

* 9. If a cap is imposed, would exempting clinical trials from the proposed cap benefit your company?

Question Title

* 10. Would the $2M cap impact your ability to compete globally? If yes, how?